DIP Episode 10 - Comprehensive GI Pharmacology

Source / episode info

• Episode: 10
• Title: Divine Intervention Episode 10 – Comprehensive GI Pharmacology.
• Published: 2018-03-24
• Source: Episode page

One-liner

Episode 10 provides a comprehensive review of GI pharmacology, covering laxatives (CaCO_3, Al(OH)_3), anti-emetics (5-HT_3 antagonists, D2 blockers), acid secretion physiology and inhibitors (H2 blockers, PP Is), management of hepatic encephalopathy, and autoimmune biliary diseases (PBC/PSC).

High-yield summary

• Acid Secretion: Acid release is stimulated by Acetylcholine ({M}_3 receptors) and Gastrin (via CCKBR and histamine release); the final common pathway involves increasing intracellular cAMP.
• PP Is vs H2 Blockers: PP Is irreversibly inhibit the {H}^+/{K}^+ AT Pase pump, making them the most potent acid suppressants; they carry risks of B12 deficiency (due to reduced pepsin activity), hypomagnesemia, and increased risk of infections/fractures.
• GI Motility Agents: Prokinetics include cholinergic agonists (Bethanechol) or A ChE inhibitors (Neostigmine); motility can also be stimulated by {M}_3 receptor agonists (e.g., Bethanechol).
• Hepatic Encephalopathy: Treatment involves reducing ammonia load via Lactulose (acidifies gut, trapping {NH}_3 as non-absorbable {NH}_4^+) or using Rifaximin (non-absorbable antibiotic that reduces gut flora).
• Autoimmune Cholangitis: Primary Biliary Cholangitis (PBC) is associated with anti-mitochondrial antibodies ({AMA}) and treated with Ursodeoxycholic acid (UDCA); Primary Sclerosing Cholangitis (PSC) is associated with {p}-ANCA.

Learning objectives

• Differentiate between various GI laxatives based on their mechanism of action (osmotic, bulk-forming, etc.).
• Describe the physiological pathways regulating gastric acid secretion and identify key pharmacological targets (\text{H}_2 receptors, \text{H}^+/\text{K}^+ AT Pase).
• Apply knowledge of PPI side effects, particularly B12 deficiency, hypomagnesemia, and fracture risk.
• Outline the management strategies for hepatic encephalopathy using lactulose or rifaximin.
• Distinguish between autoimmune cholangitis patterns (PBC vs PSC) based on antibody profile and treatment.

Board exam buzzwords

Rapid review table

Board-speak -> diagnosis

Differential diagnosis / distinguishing features

Autoimmune Cholangitis

Management pearls

• For chronic glucocorticoid use, use PPI for GI prophylaxis only in selected high-risk patients (e.g., combined NSAI Ds, prior ulcer/GI bleed). Consider bisphosphonate/calcium/vit D for bone protection based on fracture risk and steroid dose/duration.
• In the setting of hepatic encephalopathy, administer Lactulose to acidify the gut and trap ammonia as non-absorbable ammonium (\text{NH}_4^+).
• The primary mechanism for treating diabetic gastroparesis is restoring parasympathetic tone using agents like Bethanechol or Neostigmine.
• When managing chronic portal hypertension, use nonselective beta-blockers (e.g., Propranolol) for prophylaxis against esophageal varices; acutely, use Octreotide.

Don't miss

Integration & clinical reasoning

• GI Tract/Electrolytes: PP Is block gastric \text{H}^+/\text{K}^+ exchange; they are not a classic cause of hypochloremic metabolic alkalosis (vomiting/NG suction are). This highlights how acid suppression can cause hypomagnesemia and alter systemic electrolyte balance.
• Pharmacology/Metabolism: Cimetidine is a potent inhibitor of CYP450 enzymes, meaning co-administration with other drugs can increase their plasma concentrations and toxicity risk.
• GI Tract/Microbiology: The use of Rifaximin demonstrates the concept that non-absorbable antibiotics can be used to modify gut flora composition (e.g., reducing ammonia production) without systemic side effects.

OMM / COMLEX integration

• For any acute GI pathology (e.g., severe gastroenteritis, suspected bowel obstruction), standard supportive care and surgical consultation take priority over OMT.
• When managing chronic conditions like PUD or GERD, understanding the role of acid suppression is crucial for preventing complications that could lead to aspiration pneumonia, which requires meticulous airway management.

Concept connections / cross-references

• No explicit cross-references.

High-yield association table

Key terms glossary

Study optimization

Question pattern recognition

• Mechanism of Action: Identifying which specific enzyme or receptor is blocked/activated by a given drug (e.g., \text{H}^+/\text{K}^+ AT Pase inhibition by PP Is).
• Differential Diagnosis: Distinguishing between similar autoimmune conditions based on serology and anatomical involvement (PBC vs PSC).
• Side Effect Prediction: Predicting adverse effects based on the drug's mechanism (e.g., B12 deficiency from acid suppression, hypomagnesemia/fractures from PPI use).

Test yourself

Common mistakes to avoid

Common traps